The Stephenson Cancer Center (SCC) at the University of Oklahoma Health Sciences Center (OUHSC) is applying to become a Lead Academic Site in the National Clinical Trials Network (NCTN). The SCC has been a leading accrual site for the NCTN, averaging 205 patients enrolled annually on CTEP trials over the past six years. Leading this effort are SCC Director Robert Mannel, MD (Contact PI) and Associate Director for Clinical Research Scott McMeekin, MD (PI). Both PIs have an outstanding record of scientific and administrative leadership. Along with the grant Investigators, they clearly demonstrate an ability and commitment to function as a coordinated research team and work effectively with components across the NCTN. The SCC is currently a primary institution for Gynecologic Oncology Group (GOG), Radiation Therapy Oncology Group (RTOG), and Alliance (previously CALGB). In addition, it registers patients on ECOG and SWOG trials through the CTSU mechanism and actively participates with ACRIN. The SCC has been a leader for the past decade in the design and conduct of CTEP trials that have defined the standard of care for numerous malignancies. Over the past six years the SCC enrolled 1,232 patients on CTEP therapeutic trials, including an all-time institutional high of 238 patients in 2012 (with projecte enrollment of 258 in 2013), making it a national leader in accrual for the NCTN. As a Lead Academic Site the SCC will continue to work with Network coordinating centers to be a leader in the design and conduct of NCTN trials for newly-developed therapies, including multi-modality treatments, combinations of novel agents, molecularity-based treatments, advanced imaging approaches, quality biospecimen acquisition and translational research. It will accomplish this goal within the context of providing high-quality cancer care and access to NCTN clinical trials for Oklahomans, especially for the state's special populations that experience significantly high rates of cancer health disparities. As the state's only academic cancer center, the SCC plays a crucial role in providing all Oklahomans access to NCTN clinical trials, definitively evaluating novel therapies, raising the standard of care and easing the burden of cancer for the region.

Public Health Relevance

This proposal is directly relevant to public health. As a Lead Academic Site in the NCTN, the SCC will directly contribute to the design and conduct of definitive, randomized, early and late Phase clinical trials for newly-developed therapies, including multi-modality treatments, combinations of novel agents, molecularity- based treatments, and advanced imaging approaches. The ultimate goal is to improve the health of all populations, with an emphasis on special populations such as American Indians.

National Institute of Health (NIH)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Oklahoma Health Sciences Center
Obstetrics & Gynecology
Schools of Medicine
Oklahoma City
United States
Zip Code
Norquist, Barbara M; Harrell, Maria I; Brady, Mark F et al. (2016) Inherited Mutations in Women With Ovarian Carcinoma. JAMA Oncol 2:482-90
Qiu, Yuchen; Tan, Maxine; McMeekin, Scott et al. (2016) Early prediction of clinical benefit of treating ovarian cancer using quantitative CT image feature analysis. Acta Radiol 57:1149-55
Moore, Kathleen N; Java, James J; Slaughter, Katrina N et al. (2016) Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis. Gynecol Oncol 143:294-301
Fader, Amanda N; Java, James; Tenney, Meaghan et al. (2016) Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis. Gynecol Oncol 143:460-465
Wright, Alexi A; Bohlke, Kari; Armstrong, Deborah K et al. (2016) Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 34:3460-73
Osborne, Raymond J; Filiaci, Virginia L; Schink, Julian C et al. (2016) Second Curettage for Low-Risk Nonmetastatic Gestational Trophoblastic Neoplasia. Obstet Gynecol 128:535-42
Tan, Maxine; Li, Zheng; Qiu, Yuchen et al. (2016) A New Approach to Evaluate Drug Treatment Response of Ovarian Cancer Patients Based on Deformable Image Registration. IEEE Trans Med Imaging 35:316-25
Hensley, Martee L; Miller, Austin; O'Malley, David M et al. (2015) Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol 33:1180-5
Kunos, Charles; Deng, Wei; Dawson, Dawn et al. (2015) A phase I-II evaluation of veliparib (NSC #737664), topotecan, and filgrastim or pegfilgrastim in the treatment of persistent or recurrent carcinoma of the uterine cervix: an NRG Oncology/Gynecologic Oncology Group study. Int J Gynecol Cancer 25:484-92
Zighelboim, Israel; Ali, Shamshad; Lankes, Heather A et al. (2015) Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 138:614-9

Showing the most recent 10 out of 26 publications